Ropes & Gray advised Apollo Therapeutics in a licensing agreement with Sunshine Lake Pharma Co., Ltd., a member of China’s HEC Group, pursuant to which Apollo Therapeutics will receive exclusive ex-China rights to develop and commercialize HEC88473, a clinical-stage FGF21/GLP-1 dual receptor agonist developed by Sunshine Lake that has potential in multiple disease areas. The transaction was announced on Nov. 12.
Under the agreement, Sunshine Lake is to receive a $12 million upfront payment and up to $926 million in development, regulatory and commercial milestone payments, in addition to royalties.
Apollo Therapeutics is a UK- and U.S.-based portfolio biopharmaceutical company that has over 20 active therapeutic programs and is building a diversified portfolio of novel therapeutics with uncorrelated risk.
The Ropes & Gray team was led by life sciences partner Rajarshi Banerjee and life sciences associate Peter Chi and included private equity partner Paul Armstrong, tax partners David Saltzman and Chris Agnoli, and litigation & enforcement partner Lisa Kaltenbrunner.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.